Page last updated: 2024-12-04

guaiacol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Guaiacol: An agent thought to have disinfectant properties and used as an expectorant. (From Martindale, The Extra Pharmacopoeia, 30th ed, p747) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methylcatechol : Any member of the class of catechols carrying one or more methyl substituents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

guaiacol : A monomethoxybenzene that consists of phenol with a methoxy substituent at the ortho position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID460
CHEMBL ID13766
CHEBI ID28591
SCHEMBL ID21626
MeSH IDM0009668

Synonyms (175)

Synonym
AB00876226-06
pyrocatechol monomethyl ether
guaicol
o-guaiacol
nsc3815
guajol
wln: qr bo1
phenol, 2-methoxy-
guaicolina
phenol, o-methoxy-
o-methyl catechol
pyroguaiac acid
nsc-3815
guaiastil
o-hydroxyanisole
guasol
anastil
CHEBI:28591 ,
smr000059155
MLS001055375
wood creosote
D00117
guaiacol (jan)
creodon (tn)
creosote
inchi=1/c7h8o2/c1-9-7-5-3-2-4-6(7)8/h2-5,8h,1h
NCGC00090827-02
creosote, wood
NCGC00090827-03
8021-39-4
NCGC00090827-01
hsdb 4241
guaiacol (natural)
nsc 3815
ai3-05615
guajacol
fema no. 2532
methylcatechol
pyrocatechol methyl ester
einecs 201-964-7
guaiacol [jan]
guajakol [czech]
ccris 2943
2-methoxyphenol
1-hydroxy-2-methoxybenzene
90-05-1
o-methoxyphenol
o--methoxyphenol
catechol mono methyl ether
2-hydroxyanisole
C01502
catechol monomethyl ether
guaiacol
9009-62-5
GHL.PD_MITSCHER_LEG0.900
guaiacol, natural, >=99%, fg
guaiacol, oxidation indicator
2-methoxy-phenol
catechol, methyl
2-hydroxy-anisole
jz3 ,
ortho-methoxyphenol
HMS2089D18
bdbm50240369
AKOS000118831
methoxyphenol
phenol, methoxy-
BMSE000436
creodon
(mu)-methoxyphenol
CHEMBL13766 ,
BMSE010027
M0121
A843426
NCGC00090827-04
NCGC00090827-06
NCGC00090827-05
dtxsid0023113 ,
tox21_400004
dtxcid003113
cas-90-05-1
tox21_202990
dsstox_cid_3113
dsstox_gsid_24853
tox21_201136
NCGC00260535-01
dsstox_rid_77552
NCGC00258688-01
cas-8021-39-4
nsc-760376
pharmakon1600-01506165
nsc760376
tox21_111031
HMS2233P04
S3872
STL281868
FT-0671312
6jka7mah9c ,
ec 201-964-7
guaiacol [jan:nf]
unii-6jka7mah9c
guajakol
FT-0626815
PS-3252
guaiacol [vandf]
guaiacol [hsdb]
guaiacol [usp-rs]
guaiacol [ep monograph]
2-methoxyl-4-vinylphenol
guaifenesin impurity a [ep impurity]
guaiacol [fhfi]
guaiacol [usp impurity]
guaiacol [who-dd]
guaiacol [mi]
guaiacol [mart.]
HMS3372N11
CCG-214035
SCHEMBL21626
NCGC00090827-07
6-methoxyphenol
orthomethoxyphenol
methoxy phenol
2-methoxy phenol
2-(methyloxy)phenol
STR03604
AC-34997
Q-100002
methylcatachol
ortho-guaiacol
o-guiacol
AB00876226_07
mfcd00002185
20189-11-1
o-methylcatechol
F2173-0425
SR-01000838056-3
CS-D1347
SR-01000838056-2
sr-01000838056
guaiacol, saj first grade, >=98.0%
guaiacol, united states pharmacopeia (usp) reference standard
guaiacol, vetec(tm) reagent grade, 98%
guaiacol, puriss., 99%
guaiacol, european pharmacopoeia (ep) reference standard
guaiacol, pharmaceutical secondary standard; certified reference material
2-methoxyphenol (guaiacol)
HMS3715E11
guaiacol (liquid) extra pure
guiacol
o-methoxy-phenol
DB11359
Q412403
HY-N1380
2-methoxyphenol-3,4,5,6-d4,od
guaiacol,(s)
BCP27082
2-methoxyphenol;o-methoxyphenol;2-hydroxyanisole
hydroxyl anisole
3-methoxy-4-hydroxy benzene
2-methoxy-d3-phenol--d4
EN300-19498
SY048708
PB43791
creasote
2-methyloxyphenol
F70227
guaiacol (usp-rs)
o-hydroxyaniosole
guaiacol (usp impurity)
guaiacol (mart.)
fema no 2532
guaiacol (ep monograph)
guaifenesin impurity a (ep impurity)
o-methoxy catechol
Z104474028

Research Excerpts

Overview

Guaiacol is a compound with an undesirable odour ("medicinal", "smoked" or "antiseptic") It is a substrate for all peroxidases.

ExcerptReferenceRelevance
"Guaiacol is a compound with an undesirable odour ("medicinal", "smoked" or "antiseptic")."( Occurrence of Alicyclobacillus acidoterrestris in pasteurized and high hydrostatic pressure-treated fruit juices and isolates' characterization.
Alegre, I; Colás-Medà, P; Garza, S; Neggazi, I; Viñas, I, 2023
)
1.63
"Guaiacol is a universal substrate for all peroxidases, and its use in a simple colorimetric assay has wide applications. "( Crystal structure of guaiacol and phenol bound to a heme peroxidase.
Metcalfe, CL; Moody, PC; Murphy, EJ; Nnamchi, C; Raven, EL, 2012
)
2.14
"Guaiacol is a compound used as expectorant. "( Acute toxicity of guaiacol administered subcutaneously in the mouse.
Campos Sepúlveda, AE; Chauvet, D; Del Villar, A; Lopez Valle, A; Martínez Enriquez, ME; Susano Pompeyo, M, 2009
)
2.13
"Guaiacol, which is a phenolic compound with a methoxy group and used in traditional dental pulp sedation, has the property of inducing cell proliferation. "( Hydroxyl radical scavenging effects of guaiacol used in traditional dental pulp sedation: reaction kinetic study.
Kawaguchi, M; Mimurai, T; Ozawa, T; Sawaki, K; Yazaki, K, 2005
)
2.04

Effects

Guaiacol oxidation has been considered to be a more reliable method than the iodide one. The moiety is found in antiinflammatory compounds present in traditional african or chinese medicine.

ExcerptReferenceRelevance
"Guaiacol oxidation has been considered to be a more reliable method than the iodide one, especially when the substrate concentration and temperature vary, and when the activity of relatively rich in protein samples, as well as of some other substances that might interfere with the I3- formation, are going to be measured."( Some limitation in the use of the I- method for measuring the peroxidase activity from bovine thyroid gland.
Iborra, JL; Lozano, JA; Salano, F, 1981
)
0.98
"Guaiacol moiety has been found in antiinflammatory compounds present in traditional african or chinese medicine. "( [Substituted methoxyphenol with antioxidative activity: correlation between physicochemical and biological results].
Crastes de Paulet, A; Labidalle, S; Limasset, B; Michel, F; Nepveu, F; Souchard, JP, 1995
)
1.73

Treatment

ExcerptReferenceRelevance
"Guaiacol treatment in the APBD mouse model rescued grip strength and shorter lifespan."( Guaiacol as a drug candidate for treating adult polyglucosan body disease.
Akman, HO; Alvarez, R; Escriba, P; Ferreira, I; Kakhlon, O; Khazanov, N; Lossos, A; Pampou, S; Senderowitz, H; Solmesky, LJ; Weil, M; Yetil, D; Yue, WW, 2018
)
2.64

Toxicity

ExcerptReferenceRelevance
"In vivo ethylenebisdithiocarbamates and ETU are toxic to the thyroid gland."( Thyroid peroxidase as toxicity target for dithiocarbamates.
Corsini, E; Galli, CL; Ghilardi, F; Guizzetti, M; Marinovich, M; Viviani, B, 1997
)
0.3
" Further chemical characterization of the polar and polyaromatic fractions is required to fully assess the potential of health and ecological risks at the creosote-and petroleum-contaminated sites exhibiting these toxic responses."( Toxicity and mutagenicity of component classes of oils isolated from soils at petroleum- and creosote-contaminated sites.
Hrudey, SE; Kenefick, SL; Pollard, SJ; Zemanek, MG, 1997
)
0.3
"7 mg/l in the elutriate of the uppermost (0-10 cm) layer, also being the most toxic to photoluminencent bacteria and water flea."( The toxicity and concentrations of PAHs in creosote-contaminated lake sediment.
Hyötyläinen, T; Oikari, A, 1999
)
0.3
" The challenge is to develop methods that assign risk to the bioavailable toxic contaminants, thereby protecting ecosystems, while balancing remediation costs."( Acute ecotoxicity of creosote-contaminated soils to Eisenia fetida: a survival-based approach.
Charrois, JW; Froese, KL; McGill, WB, 2001
)
0.31
" Toxicity decreased concurrently with the decrease in PAH concentration during composting, but after 4 months, one of the piles inoculated with mycobacteria and containing more three- and four-ring compounds was found to be more toxic than at the beginning."( Microbial toxicity tests and chemical analysis as monitoring parameters at composting of creosote-contaminated soil.
Ahtiainen, J; Järvinen, M; Joutti, A; Valo, R, 2002
)
0.31
" Of the subjects, 27% (12/45) receiving wood creosote and 27% (4/15) receiving placebo reported adverse events."( Multiple-dose escalation, safety, and tolerability study of wood creosote, the principal active ingredient of seirogan, an herbal antidiarrheal medication, in healthy subjects.
Kuge, T; Shibata, T; Willett, MS, 2003
)
0.32
" The most common adverse events were mild headache and dizziness, with no dose-related trends being apparent."( Wood creosote, the principal active ingredient of seirogan, an herbal antidiarrheal medicine: a single-dose, dose-escalation safety and pharmacokinetic study.
Kuge, T; Shibata, T; Willett, MS, 2003
)
0.32
"Single oral doses of wood creosote up to 225 mg were safe and well tolerated in healthy men and women."( Wood creosote, the principal active ingredient of seirogan, an herbal antidiarrheal medicine: a single-dose, dose-escalation safety and pharmacokinetic study.
Kuge, T; Shibata, T; Willett, MS, 2003
)
0.32
" We concluded that guaiacol is an extremely toxic product (toxic rating class 5) whose use should be restricted or banned."( Acute toxicity of guaiacol administered subcutaneously in the mouse.
Campos Sepúlveda, AE; Chauvet, D; Del Villar, A; Lopez Valle, A; Martínez Enriquez, ME; Susano Pompeyo, M, 2009
)
1.02
" The present study was designed to investigate the possibility of coal tar creosote to induce oxidative stress and biochemical perturbations in rat liver and the role of rosemary (Rosmarinus officinalis) in ameliorating its toxic effects."( Oxidative stress modulation by Rosmarinus officinalis in creosote-induced hepatotoxicity.
Abbady, EA; Baghdadi, HH; El-Demerdash, FM, 2016
)
0.43
" Nephrotoxicity is the most common limiting side effect of cisplatin use."( Protective effects of zingerone on oxidative stress and inflammation in cisplatin-induced rat nephrotoxicity.
Alibakhshi, T; Khodayar, MJ; Khorsandi, L; Rashno, M; Zeidooni, L, 2018
)
0.48
"Among the heavy metal poisonings, lead is considered as a major toxic metal causing hematological, neurological, immunological, hepatic, and renal dysfunctions."( Zingerone prevents lead-induced toxicity in liver and kidney tissues by regulating the oxidative damage in Wistar rats.
Ahmad, P; Ahmad, SB; Amin, I; Arafah, A; Ganaie, SA; Hussain, I; Mir, BA; Mir, MUR; Muzamil, S; Rehman, MU; Shanaz, S, 2021
)
0.62
" Its dose must be commonly monitored according to pain status and to alleviate the appearance of any adverse effects such as renal cellular damage during its excretion."( 10-Dehydrogingerdione Attenuates Tramadol-Induced Nephrotoxicity by Modulating Renal Oxidative Stress, Inflammation and Apoptosis in Experimental Rats: Role of HO-1 Activation and TLR4/NF-κB/ERK Inhibition.
Al-Gabri, NA; Alnomasy, SF; Althafar, ZM; Elkomy, NMIM; Elnagar, GM; Elseweidy, MM; Mahmoud, YK; Shawky, M, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
"Wood creosote, principally a mixture of non-, alkyl- and/or alkoxy-substituted phenolic compounds, was orally administered to adult male volunteers to determine its metabolites and pharmacokinetic parameters."( Pharmacokinetics of wood creosote: glucuronic acid and sulfate conjugation of phenolic compounds.
Matsushima, N; Ogata, N; Shibata, T, 1995
)
0.29

Compound-Compound Interactions

ExcerptReferenceRelevance
" Since the interest of common people in herbal medicines and self-medication has been increasing, the use of wood creosote has also been modified in combination with some herbal drugs, "Seiro-gan" especially is quite popular in Japan as a self-medication for digestive trouble, including food poisoning or diarrhea."( [Wood creosote: a historical study and its preparation in combination with herbal drugs].
Baba, T; Tani, T, 2001
)
0.31
" To find and identify further guaiacol conjugates in smoke-affected grapes, a stable isotope feeding experiment combined with extensive HPLC-MS and MS/MS investigations was carried out."( Investigation into the formation of guaiacol conjugates in berries and leaves of grapevine Vitis vinifera L. Cv. cabernet sauvignon using stable isotope tracers combined with HPLC-MS and MS/MS analysis.
Baldock, GA; Hayasaka, Y; Herderich, MJ; Jeffery, DW; Pardon, KH, 2010
)
0.92
"To study the anti-cataract effect of gigantol combined with syringic acid and their action mechanism."( [Study on anti-cataract effect of gigantol combined with syringic acid and their mechanism].
Diao, H; Fang, H; Gao, X; Gu, L; Gu, Q; Qi, H; Wang, L; Wang, Z; Wei, X; Yi, Y, 2012
)
0.38
"H202-induced lens oxidative injury in vitro rat model was establish to observe the impact of gigantol combined with syringic acid on lens transparency under a dissecting microscope."( [Study on anti-cataract effect of gigantol combined with syringic acid and their mechanism].
Diao, H; Fang, H; Gao, X; Gu, L; Gu, Q; Qi, H; Wang, L; Wang, Z; Wei, X; Yi, Y, 2012
)
0.38
"Gigantol combined with syringic acid shows good anti-cataract, their action mechanism is reflected in their good collaborative inhibitory effect on AR."( [Study on anti-cataract effect of gigantol combined with syringic acid and their mechanism].
Diao, H; Fang, H; Gao, X; Gu, L; Gu, Q; Qi, H; Wang, L; Wang, Z; Wei, X; Yi, Y, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" In additional experiments the absorption rate of tetrachloroveratrol was measured in free swimming fish."( The absorption of hydrophobic chemicals across perfused rainbow trout gills: methodological aspects.
Havaste, K; Pärt, P; Saarikoski, J; Tuurala, H, 1992
)
0.28
" Bioavailability of mutagens in the biopile soil was determined with six solvents; water-soluble mutagens accounted for 40% of the total mutagenic activity and they were stable at room temperature."( Genotoxicity of bioremediated soils from the Reilly Tar site, St. Louis Park, Minnesota.
Brenner, R; Brooks, L; Claxton, LD; Hughes, TJ; Kremer, F; Warren, S, 1998
)
0.3
" Contaminant endpoints need to be established that consider the bioavailability of toxicants in soil."( Acute ecotoxicity of creosote-contaminated soils to Eisenia fetida: a survival-based approach.
Charrois, JW; Froese, KL; McGill, WB, 2001
)
0.31
"Two common reasons to explain slow environmental biodegradation of polycyclic aromatic hydrocarbons (PAHs), namely lack of appropriate carbon sources for microbial growth and limited bioavailability of PAHs, were tested in a laboratory bioassay using a creosote-contaminated soil."( Effects of carbon substrate enrichment and DOC concentration on biodegradation of PAHs in soil.
Bengtsson, G; Zerhouni, P, 2003
)
0.32
"The bioavailability of polycyclic aromatic hydrocarbons (PAHs) to benthic organisms is complicated by the variety of ways that they are introduced to coastal waters (dissolved, as nonaqueous phase liquids, and tightly bound to soot, coal, tire rubber, and eroded shale)."( Role of source matrix in the bioavailability of polycyclic aromatic hydrocarbons to deposit-feeding benthic invertebrates.
Brownawell, BJ; Burgess, RM; Cantwell, MG; McElroy, AE; Rust, AJ, 2004
)
0.32
" Pyrogenic PAHs, particularly those associated with combustion particles (soot), have a low accessibility and bioavailability in sediments."( Ecological risk assessment of polycyclic aromatic hydrocarbons in sediments: identifying sources and ecological hazard.
Gunster, DG; Neff, JM; Stout, SA, 2005
)
0.33
" It is hypothesized that the lack of PAH bioavailability hampered their further biodegradation in the unspiked soil."( Microbial populations related to PAH biodegradation in an aged biostimulated creosote-contaminated soil.
Jiménez, N; Lladó, S; Solanas, AM; Viñas, M, 2009
)
0.35
" While earthworm and plant assays indicated that PAH bioavailability was reduced following ENA, the residual PAH fraction still exerted toxicological impacts on both receptors."( Bioavailability of residual polycyclic aromatic hydrocarbons following enhanced natural attenuation of creosote-contaminated soil.
Juhasz, AL; Smith, E; Stewart, R; Waller, N; Weber, J, 2010
)
0.36
" viminalis or the surfactant enhanced PAH degradation, primarily by a rhizosphere effect on the microbial activity in the former case and by increased bioavailability in the latter case."( Degradation of PAH in a creosote-contaminated soil. A comparison between the effects of willows (Salix viminalis), wheat straw and a nonionic surfactant.
Castillo, Mdel P; Granhall, U; Hultgren, J; Pizzul, L, 2010
)
0.36
"In this study, PAH bioavailability was assessed in creosote-contaminated soil following bioremediation in order to determine potential human health exposure to residual PAHs from incidental soil ingestion."( In vivo measurement, in vitro estimation and fugacity prediction of PAH bioavailability in post-remediated creosote-contaminated soil.
Gancarz, D; Juhasz, AL; Rofe, A; Slee, D; Smith, E; Stevenson, G; Weber, J, 2014
)
0.4
" The overall removal of PAHs was determined to be mass transport limited since the dissolution rate caused by the biosurfactant enhanced the bioavailability of the PAHs to the microorganisms."( Biosurfactant-enhanced bioremediation of aged polycyclic aromatic hydrocarbons (PAHs) in creosote contaminated soil.
Bezza, FA; Chirwa, EM, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Their hydrophobic character and low bioavailability to soil microorganisms affects their rate of biodegradation."( Bacteria involved in biodegradation of creosote PAH - A case study of long-term contaminated industrial area.
Kaczorek, E; Smułek, W; Sydow, M; Zabielska-Matejuk, J, 2020
)
0.56
"Even though many fungi are known to degrade a range of organic chemicals and may be advantageous for targeting hydrophobic chemicals with low bioavailability due to their ability to secrete extracellular enzymes, fungi are not commonly leveraged in the context of bioremediation."( Investigating the mycobiome of the Holcomb Creosote Superfund Site.
Cooper, EM; Czaplicki, LM; Ferguson, PL; Gunsch, CK; Redfern, LK; Vilgalys, R, 2020
)
0.56
"This study sought to prepare a self-microemulsion drug delivery system containing zingerone (Z-SMEDDS) to improve the low oral bioavailability of zingerone and anti-tumor effect."( Improvement of Oral Bioavailability and Anti-Tumor Effect of Zingerone Self-Microemulsion Drug Delivery System.
Adu-Frimpong, M; Bao, R; Cao, X; Wang, QL; Wang, YP; Wei, CM; Weng, W; Xu, XM; Yu, JN; Zhu, Q, 2021
)
0.62
"Herein, a nano-micelle drug delivery system was developed to orally improved zingerone's bioavailability and its antitumor effect."( Improved oral bioavailability, cellular uptake, and cytotoxic activity of zingerone via nano-micelles drug delivery system.
Ge, Z; Wang, Q; Xu, X; Yu, J; Yusif, M; Zhu, Q, 2021
)
0.62

Dosage Studied

The application of the guaiacolsulfonate potassium assay method to commercial dosage forms is reported. Dose-response curves were performed by subcutaneous administration (6.5 mg/kg)

ExcerptRelevanceReference
"A method for the quantitative determination of potassium guaiacolsulfonate and phenylephrine hydrochloride in commercial dosage forms was developed."( Applications of paired ion high-pressure liquid chromatography: quantitative determination of potassium guaiacolsulfonate and other ingredients in cough syrups.
Gupta, VD, 1979
)
0.72
" Oral or intraperitoneal dosage (100mg/kg) of zingerone resulted in the urinary excretion of most metabolites within 24 h, mainly as glucuronide and/or sulphate conjugates."( The metabolism of zingerone, a pungent principle of ginger.
Monge, P; Scheline, R; Solheim, E, 1976
)
0.26
" Oral dosage (100 mg/kg) of the aldehyde resulted in urinary excretion of most metabolites within 24 h, mainly as glucuronide and/or sulphate conjugates although the acids formed were also excreted free and as their glycine conjugates."( The metabolism of vanillin and isovanillin in the rat.
Scheline, RR; Strand, LP, 1975
)
0.25
" The application of the guaiacolsulfonate potassium assay method to commercial dosage forms is reported."( Colorimetric determinations of chlorpheniramine maleate, ephedrine hydrochloride, and guaiacolsulfonate potassium in a cough syrup.
Das Gupta, V; de Lara, AJ, 1975
)
0.78
", direct dosing without filtration, diluting the stock solution of saturated concentration, and dispersing with acetone."( Aquatic toxicity testing for multicomponent compounds with special reference to preparation of test solution.
Hwang, DF; Kawashima, Y; Kitano, M; Maeda, M; Tadokoro, H; Yoshida, T, 1991
)
0.28
" The semialkaline proteolithic enzyme Seaprose S, available in 30 mg tablets was administered at a dosage of 3 tablets a day for a period of 8 days."( [Clinical effectiveness and safety of Seaprose S in the treatment of complications of puerperal surgical wounds].
Candotti, G; Dindelli, M; Frigerio, L; Pifarotti, G; Potenza, MT,
)
0.13
") shifted these dose-response curves in parallel to the right."( The selective capsaicin antagonist capsazepine abolishes the antinociceptive action of eugenol and guaiacol.
Ohkubo, T; Shibata, M, 1997
)
0.51
" Oral granules of nimesulide were administered in daily dosage of 200 mg."( [Controlled clinical study of the efficacy and tolerability of methoxybutropate compared to nimesulide in gynecology].
Ajossa, S; Guerriero, S; Mais, V; Melis, GB; Paoletti, AM, 1997
)
0.3
" In order to assess toxicological risks of sediment contents to fish, juvenile rainbow trout (Onchorhynchus mykiss) were intraperitoneally dosed with extracts of the creosote-contaminated sediments and their elutriates."( Assessment of the bioactivity of creosote-contaminated sediment by liver biotransformation system of rainbow trout.
Hyötyläinen, T; Oikari, A, 1999
)
0.3
" Rainbow trout were placed in 12,000-L outdoor microcosms dosed with 0, 3, or 10 microl/L liquid creosote for a 28-day period."( Effect of maintaining rainbow trout in creosote microcosms on lens optical properties and liver 7-ethoxyresorufin-O-deethylase (EROD) activity.
Bols, NC; Dixon, DG; Herbert, KL; Karrow, NA; Sivak, JG; Whyte, JJ, 2000
)
0.31
" Fish were sampled on d 7, 14, 21, and 28 from microcosms dosed initially with 0, 3, and 10 microl/L of creosote."( Effects of creosote exposure on rainbow trout pronephros phagocyte activity and the percentage of lymphoid B cells.
Boermans, HJ; Bols, NC; Dixon, DG; Karrow, NA; Solomon, KR; Whyte, JJ, 2001
)
0.31
" The present study was designed to assess the safety and tolerability of an anticipated acute antidiarrheal dosing regimen."( Multiple-dose escalation, safety, and tolerability study of wood creosote, the principal active ingredient of seirogan, an herbal antidiarrheal medication, in healthy subjects.
Kuge, T; Shibata, T; Willett, MS, 2003
)
0.32
"0 mg/hr) reduced trap catches of baited traps in a dose-response manner."( A 4-alkyl-substituted analogue of guaiacol shows greater repellency to savannah tsetse (Glossina spp.).
Hassanali, A; Saini, RK, 2007
)
0.62
" The optimal dosage of reagents was determined by a statistical method, the central composite rotatable experimental design."( Oxidation by Fenton's reagent combined with biological treatment applied to a creosote-comtaminated soil.
Alessandri, R; Aunola, T; Cortina, JL; Gamisans, X; Tuhkanen, T; Valderrama, C, 2009
)
0.35
" Here, we examined mtDNA and nDNA damage in the Atlantic killifish (Fundulus heteroclitus) from a highly contaminated Superfund site (Elizabeth River, VA, USA) and from a reference site (King's Creek, VA, USA) that were dosed with 10 mg/kg BaP."( Effects of benzo[a]pyrene on mitochondrial and nuclear DNA damage in Atlantic killifish (Fundulus heteroclitus) from a creosote-contaminated and reference site.
Cho, Y; Collins, LB; Di Giulio, RT; Jung, D; Swenberg, JA, 2009
)
0.35
" The effect of pH, temperature, H(2)O(2) dosing rate, initial concentration of Fe(2+), and initial COD was investigated using the Fenton process."( Kinetic degradation of the pollutant guaiacol by dark Fenton and solar photo-Fenton processes.
Abdelhédi, R; Samet, Y; Wali, I, 2011
)
0.64
" Dose-response curves to guaiacol were performed by subcutaneous administration (6."( Acute toxicity of guaiacol administered subcutaneously in the mouse.
Campos Sepúlveda, AE; Chauvet, D; Del Villar, A; Lopez Valle, A; Martínez Enriquez, ME; Susano Pompeyo, M, 2009
)
0.99
" In conclusion, although we found no associations with PAH metabolites in urine (short-term exposure), our results suggest dose-response relationship between PAH exposure and DNA hypomethylation of lung cancer-related loci."( DNA methylation of the cancer-related genes F2RL3 and AHRR is associated with occupational exposure to polycyclic aromatic hydrocarbons.
Albin, M; Alhamdow, A; Broberg, K; Graff, P; Gustavsson, P; Hagberg, J; Krais, AM; Lindh, C; Tinnerberg, H; Westberg, H, 2018
)
0.48
" Variables such as vine-shoot vinifera (Airén and Cencibel), size (chip and granule), toasting (toasted and non-toasted), dosage (4 and 12 g/L) and maceration time (1, 7, 21, 35 and 120 days) were tested."( Assessment of vine-shoots in a model wines as enological additives.
Alonso, GL; Amaya, Z; Cristina, CT; Miguel, CJ; Rosario, SG; Rosario, SM, 2019
)
0.51
" Commercially available syrup dosage form was successfully analyzed by the developed methods without interference from formulation additives."( Bilinear and trilinear algorithms utilizing full and selected variables for resolution and quantitation of four components with overlapped spectral signals in bulk and syrup dosage form.
Boltia, SA; Fayed, AS; Hegazy, MA; Musaed, A, 2019
)
0.51
" The mammary carcinogenesis was produced through a single dosage of DMBA (20 mg/kg bwt) mixed in soya oil (1 mL) administrated intragastrically with a gavage."( Zingerone induced caspase-dependent apoptosis in MCF-7 cells and prevents 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in experimental rats.
Gan, H; Mohan, SK; Veeraraghavan, VP; Xie, X; Zhang, Y; Zheng, L; Zhou, Q, 2019
)
0.51
" La performance multifonctionnelle de l’AZ comme agent antioxydant, absorbant et éliminateur a été établie à l’aide de dosages chimiques in vitro standard pour l’industrie, après quoi son efficacité à un dosage plus biologique a été confirmée par sa capacité in vitro à réduire les taux intracellulaires d’espèces réactives de l’oxygène (ROS) dans les kératinocytes exposés au rayonnement UV."( Acetyl zingerone: An efficacious multifunctional ingredient for continued protection against ongoing DNA damage in melanocytes after sun exposure ends.
Brash, D; Chaudhuri, RK; Meyer, T; Premi, S, 2020
)
0.56
" Lure dosage had a significant effect on the duration of the mating advantage, for example when fed 20 µg of zingerone, the advantage lasted only 1 day post-feeding, but when fed of 50 µg zingerone the advantage lasted 7 days."( Male-lure type, lure dosage, and fly age at feeding all influence male mating success in Jarvis' fruit fly.
Clarke, AR; Wee, SL, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
expectorantCompounds that are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing. Compare with mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration, and antitussives, which suppress the cough reflex.
disinfectantAn antimicrobial agent that is applied to non-living objects to destroy harmful microorganisms or to inhibit their activity.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
EC 1.1.1.25 (shikimate dehydrogenase) inhibitorAn EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of shikimate dehydrogenase (EC 1.1.1.25).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
guaiacolsAny phenol carrying an additional methoxy substituent at the ortho-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (21)

PathwayProteinsCompounds
Tyrosine Metabolism1657
Alkaptonuria1657
Hawkinsinuria1657
Tyrosinemia Type I1657
Disulfiram Action Pathway2366
Tyrosinemia, Transient, of the Newborn1657
Dopamine beta-Hydroxylase Deficiency1657
Monoamine Oxidase-A Deficiency (MAO-A)1657
phenylpropanoid volatiles glycoconjugation (tomato)17
guaiacol biosynthesis25
superpathway of pyrimidine deoxyribonucleosides degradation738
ethanol degradation I415
ethanolamine utilization1336
superpathway of purine deoxyribonucleosides degradation637
mixed acid fermentation3276
superpathway of N-acetylneuraminate degradation3979
guaiacylglycerol-u03B2-guaiacyl ether degradation615
L-threonine degradation IV415
superpathway of L-threonine metabolism2172
2'-deoxy-u03B1-D-ribose 1-phosphate degradation428
pyruvate fermentation to ethanol I1020

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency5.62340.044717.8581100.0000AID485294
pregnane X receptorRattus norvegicus (Norway rat)Potency79.43280.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency69.00830.006038.004119,952.5996AID1159521
ATAD5 protein, partialHomo sapiens (human)Potency0.58020.004110.890331.5287AID504467
GLI family zinc finger 3Homo sapiens (human)Potency10.93710.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency35.44870.000221.22318,912.5098AID588515; AID743035; AID743042
thyroid stimulating hormone receptorHomo sapiens (human)Potency5.01190.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency27.52830.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency69.00830.001022.650876.6163AID1224838
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency62.01460.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency73.21840.003041.611522,387.1992AID1159552; AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency22.05720.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency26.70730.001530.607315,848.9004AID1224841; AID1224849
farnesoid X nuclear receptorHomo sapiens (human)Potency19.61070.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency19.44920.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency17.05100.000229.305416,493.5996AID743069; AID743075; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency55.27050.001024.504861.6448AID743215
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency22.38720.035520.977089.1251AID504332
activating transcription factor 6Homo sapiens (human)Potency1.91400.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.00200.057821.109761.2679AID1159526
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency0.01260.316212.443531.6228AID924
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency7.30780.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency14.35000.000323.4451159.6830AID743065; AID743066
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.46220.000627.21521,122.0200AID743202
lethal factor (plasmid)Bacillus anthracis str. A2012Potency1.00000.020010.786931.6228AID912
Cellular tumor antigen p53Homo sapiens (human)Potency4.35410.002319.595674.0614AID651631
Integrin beta-3Homo sapiens (human)Potency0.01260.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency0.01260.316211.415731.6228AID924
Nuclear receptor ROR-gammaHomo sapiens (human)Potency0.14960.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Carbonic anhydrase 1Homo sapiens (human)Ki93.49500.00001.372610.0000AID1803139; AID416125
Carbonic anhydrase 2Homo sapiens (human)Ki83.95170.00000.72369.9200AID1803139; AID416126
Carbonic anhydrase 4Homo sapiens (human)Ki100.15400.00021.97209.9200AID1803139
Carbonic anhydrase 6Homo sapiens (human)Ki100.15400.00011.47109.9200AID1803139
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (236)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (66)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (66)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (92)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1198410Fungicidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 48 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1893771Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID26793Partition coefficient (logP)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID23251Partition coefficient (logP)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID23255Partition coefficient (logP) (ether)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1420910Antioxidant activity assessed as DPPH free radical scavenging activity2018European journal of medicinal chemistry, Oct-05, Volume: 158Antibacterial and antioxidant activities for natural and synthetic dual-active compounds.
AID309363Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear oedema at 0.3 umol/cm^2 after 6 hrs2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Synthesis and anti-inflammatory activity of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives.
AID1090866Toxicity against third-instar larval stage of Trichoplusia ni (cabbage looper) assessed as mortality at 0.25% measured after 24 hr by contact toxicity bioassay2007Journal of agricultural and food chemistry, Dec-12, Volume: 55, Issue:25
Screening of dialkoxybenzenes and disubstituted cyclopentene derivatives against the cabbage looper, Trichoplusia ni, for the discovery of new feeding and oviposition deterrents.
AID416125Inhibition of human erythrocyte CA1 esterase activity using 4-nitrophenyl acetate substrate2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.
AID23252Partition coefficient (logP) (benzene)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1198409Anticandidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 24 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID1571461Antiproliferative activity against human IN1472 cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID26261Partition coefficient (logD7.2)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1571462Antiproliferative activity against human IN1528 cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID25611Dissociation constant (pKa)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1198411Anticandidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 24 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1090868Feeding deterrent activity against freshly molted third-instar larval stage of Trichoplusia ni (cabbage looper), Trichoplusia ni at 50 ug/cm'2 after 3 to 5 hr by leaf disk choice bioassay2007Journal of agricultural and food chemistry, Dec-12, Volume: 55, Issue:25
Screening of dialkoxybenzenes and disubstituted cyclopentene derivatives against the cabbage looper, Trichoplusia ni, for the discovery of new feeding and oviposition deterrents.
AID282834Activity against caspase-mediated apoptosis in mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID1571459Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID1198414Fungicidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 48 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID416126Inhibition of human erythrocyte CA2 esterase activity using 4-nitrophenyl acetate substrate2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.
AID23256Partition coefficient (logP) (hexane)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1420907Bactericidal activity against Staphylococcus aureus incubated for 24 hrs measured every 30 mins by spectrophotometric analysis2018European journal of medicinal chemistry, Oct-05, Volume: 158Antibacterial and antioxidant activities for natural and synthetic dual-active compounds.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1571463Antiproliferative activity against human IN1760 cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID1571460Antiproliferative activity against human U251MG cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1090864Oviposition deterrent activity against adult female Trichoplusia ni (cabbage looper) moths introduced along with male moths into oviposition cage containing compound pretreated cabbage leaves assessed as eggs laying on the leaf disks at 0.25% after 48 hr 2007Journal of agricultural and food chemistry, Dec-12, Volume: 55, Issue:25
Screening of dialkoxybenzenes and disubstituted cyclopentene derivatives against the cabbage looper, Trichoplusia ni, for the discovery of new feeding and oviposition deterrents.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID40936Inhibition of Bacillus subtilis PCI219 spore germination, expressed as log 1/I501982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID282833Activity against caspase-mediated apoptosis in mouse L1210 cells at 0.1 mM2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID1198412Fungicidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 48 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID1198415Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID23254Partition coefficient (logP) (chloroform)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID23253Partition coefficient (logP) (carbon tetrachloride)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1090867Feeding deterrent activity against freshly molted third-instar larval stage of Trichoplusia ni (cabbage looper) after 3 to 5 hr by leaf disk choice bioassay2007Journal of agricultural and food chemistry, Dec-12, Volume: 55, Issue:25
Screening of dialkoxybenzenes and disubstituted cyclopentene derivatives against the cabbage looper, Trichoplusia ni, for the discovery of new feeding and oviposition deterrents.
AID40623Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined.1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1198413Anticandidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 24 hrs by broth dilution method2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1803139Esterase Activity Assay from Article 10.3109/14756366.2011.637202: \\Simple methanesulfonates are hydrolyzed by the sulfatase carbonic anhydrase activity.\\2012Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 27, Issue:6
Simple methanesulfonates are hydrolyzed by the sulfatase carbonic anhydrase activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,674)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990453 (27.06)18.7374
1990's185 (11.05)18.2507
2000's348 (20.79)29.6817
2010's523 (31.24)24.3611
2020's165 (9.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.19 (24.57)
Research Supply Index7.49 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index112.96 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (64.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials25 (1.42%)5.53%
Reviews25 (1.42%)6.00%
Case Studies16 (0.91%)4.05%
Observational0 (0.00%)0.25%
Other1,692 (96.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]